Vigabatrin (VGB) has been shown in a number of clinical trials with varying designs to be effective and well-tolerated as both add-on therapy and monotherapy in epilepsy with partial seizures with or without secondary generalization as well as in infantile spasms. The present study is an open, long-term (1 year) extension of a randomized double-blind placebo-controlled multicentre Canadian trial of VGB in resistant partial adult epilepsy. The present study was designed to examine the safety and long-term efficacy of VGB.
INTRODUCTION
Vigabatrin (VGB) is an irreversible GABA transaminase inhibitor which produces a two-to three-fold rise in brain GABA concentration. It has been shown to be effective, both as an add-on agent and in monotherapy, in controlled blinded clinical trials in resistant and newly-diagnosed epilepsy . A previous Canadian multicentre double-blind study of VGB (protocol −021) reported a 48% responder rate and 52% median partial seizure reduction in adults with uncontrolled partial and secondarily generalized seizures 25 . The present study was an open follow-up study to evaluate the long-term safety and efficacy of vigabatrin in completers of the double-blind Canadian vigabatrin study.
MATERIALS AND METHODS

Inclusion/exclusion criteria
Completers of the double-blind (−021) study, 16 years of age or older, were allowed to enter the study. The patient population characteristics from which the present study drew its participants are described in the publication of the results of the previous study (Bruni et al. submitted for publication). These patients were adult patients with intractable longstanding partial epilepsy. Women of child-bearing potential were required to continue effective contraception, to sign a pregnancy waiver and undergo a pregnancy test prior to entry. Patients with a treatable cause of seizures or progressive neurological disorder; previous cranial radiotherapy; a history of frequent status epilepticus (>1 episode in preceding 6 months); significant active medical illness; significant past or present psychiatric illness, drug or alcohol abuse; non-compliance or inability to record seizures or take medication properly or known allergy to vigabatrin were all excluded from the study.
Study design
All patients signed written informed consent for the study, which had been approved by individual hospital research ethics boards. This was a multicentre study which included 10 Canadian epilepsy centres. Patients who were seizure free in the previous double-blind study at doses of VGB below 4 g/day were unblinded and allowed to continue with the same dose in the present open study. Patients who received 4 g/day in the preceding study, whether or not they were seizure free, were continued at that dose. Placebo patients entered the study at 1 g/day and all other patients at 2 g/day. Dosage was titrated upward in double-blind fashion by 1 g/day at weekly intervals and all patients were receiving 2 g b.i.d. by the third week of this study. The dose of VGB could be reduced due to adverse effects after that point.
Patients were seen and evaluated at weeks 2, 4, 6, 10, 14, 18, 22 (only if the patient was being tapered off the study drug), 26 or greater reduction of seizures on VGB compared with the baseline of the preceding double-blind study were allowed to continue. Other patients were tapered off the vigabatrin by 0.5 g/week.
Efficacy outcome measures
The efficacy outcome measures which were used were: median monthly reduction in total seizure frequency, percentage of responders (≥50% seizure reduction), seizure-free days per month, percentage of patients seizure free and physician's global assessment. Measurements were compared for the baseline period of the double-blind (−021) study, end of the double-blind study, the dose adjustment phase of the open study and the initial and the last 8 weeks of the open study.
RESULTS
Patient disposition
One hundred of the 111 patients entering the doubleblind study completed the protocol, 52 on VGB and 48 on placebo and were eligible for entry into the open study (Table 1) . Ninety-seven of these entered the open study, 95 of whom reached a VGB dose of 3 or 4 g/day and 53 of whom completed the 52 weeks of the study (49 on 4 g/day). The three patients who did not enter the study dropped out for personal or administrative reasons.
Efficacy
Responder rates (intention-to-treat) comparing the last 8 weeks of this open study with the baseline (pre-VGB) as well as with the end of the double-blind study, were 58% and 41%, respectively. There was an 85% responder rate among those completing the present study (Table 2 ). All responders in the doubleblind study maintained their response in the open study, although not all stayed on the drug. Sixty percent of those in the placebo group from the doubleblind study were responders by the end of the open study. The increase in seizure-free days per 28 days is also shown in Table 2 for the same time periods. • Worsening of seizures 1
a Withdrawal was for more than one reason in four cases. b Pregnancy (1), voluntary withdrawal (3), investigation for surgery (2). a Global evaluation included an assessment of both efficacy and tolerability.
The median total seizures per 28 days (complex partial plus secondarily generalized) for various phases of the study is shown in Fig. 1 . The data for patients receiving placebo or VGB in the double-blind study is shown separately for the open study. Comparing end of study with baseline for the VGB group and end of study with end of double-blind study for the placebo group, we note comparable seizure reduction of 5/9 (56%) and 3.3/7.3 (45%), respectively. Eleven out of 97 (11%) patients were seizure free by the end of the open study, four of whom were seizure free at the end of the double-blind study. An additional six patients who had been seizure free entering the open phase were no longer seizure free by the end of the study (Table 3). There was no significant correlation between mean trough VGB plasma concentrations and therapeutic outcome judged by responder rate or median percentage seizure reduction.
Physician's assessments of therapeutic effect at end of study show that 54% of patients had experienced at least a moderate therapeutic effect and 47% were judged to be globally at least moderately better off on the drug (Table 4 ). There were no significant differences between the study completers (n = 53) and the intention-to-treat group (n = 97) according to median age, gender, median age at onset of epilepsy, duration of epilepsy, weight or whether they derived from the placebo or treatment group in the double-blind study.
Compliance, determined by pill counts and patient reports, and defined as total tablets taken/total tablets prescribed, was 88%.
Drug interactions
There were mean decreases in phenobarbital and phenytoin plasma levels of 11% and 22%, respectively, by end of study compared with baseline.
Safety and tolerability
There were no effects on physical examination or vital signs. Ophthalmological examinations did not reveal 
a In some cases, patients may have experienced an adverse event in more than one severity category. As such, the sum of patients in each severity assessment may exceed the total number of patients.
any clinically important effects of vigabatrin on visual function, retinal vessels, the macula or optic nerve head. No effects were seen on visual fields tested by confrontation. The adverse events and their severity reported by at least 10% of patients are shown in Table 5 . All of these fell into the neurological/behavioral category and many were not persistent. The vast majority of these were judged to be mild and none were judged to be 'definitely' related to vigabatrin by the investigators. Comparing baseline (pre-VGB) with end of study, there was a mean weight gain of 3.7 ± 0.2 kg. Thirty-nine percent of patients gained ≥7% of their body weight, although 17% of patients experienced a weight reduction during the study.
There were 44 patients (45%) who were discontinued from the study: 28 (29%) for lack of clinical benefit, 1 for worsening of seizures, 12 (12%) due to adverse events and 7 (7%) for other reasons (Table 1). Four patients had two reasons for withdrawal. All adverse events leading to discontinuation were in the neurological/psychiatric category. Four of the patients discontinuing vigabatrin due to adverse events had been on the drug for over 45 weeks. There were 12 hospitalizations including 15 events classified as serious. In only 4/12 cases, all with behavioral events, were the adverse events judged to be possibly (1), probably (2) or definitely (1) related to VGB. A summary of the adverse events leading to hospitalization is a Duration of VGB treatment is defined as patient's total exposure to vigabatrin in study 021 and 022 prior to an event resulting in hospitalization. Table 7 : End of study physician's overall assessment of tolerability.
IntentionStudy to-treat completers shown in Table 6 . Physicians' overall assessments of patient tolerability at end of study showed that the drug was judged to be extremely well-tolerated in 29%, well-tolerated in 39%, fairly well-tolerated in 21% and not well-tolerated in 11% of the patients (Table 7) . Cognitive and psychosocial test battery results at mid-study and end of study compared with baseline did not show any consistent worsening trends in any of the scales or subtests. Fourteen of 21 scores on the mood and adjustment scales showed improvement and five showed worsening. Fifteen of 21 scores on the cognitive tests showed improvement and five showed worsening (Table 8) .
Clinical laboratory results were generally unremarkable and no patient was discontinued due to an abnormal laboratory value. SGPT/ALT levels were markedly reduced and SGPT/AST levels were minimally reduced. This previously-observed effect is believed to result from a nonspecific transaminase inhibition by vigabatrin. MRI studies were completed at pre-VGB baseline and end of study in 57 patients. No abnormalities or changes suggestive of intramyelinic edema were observed. The mean percentage change in evoked potential latencies was not increased at end of study compared with baseline.
DISCUSSION
In this one-year open follow-up study of previously intractable epilepsy patients who had vigabatrin added on to their previous antiepileptic drugs, 53/97 (55%) completed the 12 months of the study and 85% of these had ≥50% seizure reduction. Twenty-six of the 53 completers had received vigabatrin in the preceding double-blind study, meaning that they had been on the drug for nearly 2 years. Sixty percent of the placebo group in the preceding −021 study achieved therapeutic success (≥50% seizure reduction) in the present study and all of the vigabatrin responders in the −021 study maintained their response to the end of the present study. The overall responder rate (intentionto-treat) of 56/97 (58%) is similar to what has been reported in several other double-blind and open studies 10, 13, 20, 24 . The mean increase in seizure-free days was 3.7 days per 4-week period for the 97 patients. Eleven patients (11%) were seizure free by the end of the study. In 46% of the cases, physicians felt that they were moderately or markedly globally improved com-pared with 12% of the cases who were judged to be worse overall. It appears from our results that tolerance to the effects of vigabatrin was not a significant factor. The question of tolerance, which is common with benzodiazepines also acting by a GABAergic, although different, mechanism has been debated by previous authors. However, the tendency for responses to be retained in several long-term VGB studies suggests that tolerance is minimal 15, [26] [27] [28] [29] [30] .
Adverse events in this study were generally mild and were mainly of the 'acute neurotoxic' type (e.g. fatigue, headache, dizziness) which are relatively common in this patient population even when placebo is employed [31] [32] [33] [34] [35] . Physicians judged that in 68% of patients the drug was well tolerated or extremely well tolerated compared with only 11% in whom it was not well tolerated. The mild weight gain over the duration of the study was not clinically significant and no patient withdrew for this reason. Psychosocial and cognitive test results revealed a tendency for both mood/adjustment and cognitive scores to improve during the study. Specific studies examining the cognitive effects of vigabatrin have shown that it does not cause cognitive impairment in a variety of test batteries at therapeutic doses [36] [37] [38] . Only 13 of the 44 withdrawals (30%) were due to adverse events (including seizure exacerbation in 1/13). The 12 other withdrawals were all for neurological or behavioral side effects. Of the 12 patients who had adverse events leading to hospitalization, in only 4/12 did the physician implicate vigabatrin as a possible, probable or definite cause and 3/4 involved a behavioral adverse event. This 3% incidence of serious behavioral toxicity parallels the incidences mentioned in several other studies [39] [40] [41] [42] [43] . The behavioral reactions in these three cases were quite varied. One was a post-ictal delirium/psychosis, one a severe depression and one a psychotic reaction, suggesting that the behavioral reactions on vigabatrin may be of varied pathogenesis. The three patients had all received placebo in the preceding study and had been receiving vigabatrin for 4, 6 and 11 weeks. All recovered rapidly once the drug was withdrawn. There were no adverse effects during the one-year period of the study on physical examination findings, clinical/laboratory testing, evoked potentials or brain MRI scan.
In an open study, such as this, tolerability and sustained response to the drug are the two most important measures. We have shown that vigabatrin is exceedingly well-tolerated in this group of intractable adult epileptic patients, even when used in polytherapy. The results also show that the drug can be of long-term sustained benefit in a substantial proportion of adult patients with partial epilepsy who have not responded to conventional therapy.
